Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
D. Thaçi*, A. Kimball, P. Foley, Y. Poulin, E. Levi, R. Chen, S. R. Feldman
*Korrespondierende/r Autor/-in für diese Arbeit
33
Link öffnet neuen Tab
Zitate (Scopus)